Please assess the completion status of the following clinical trial:

Trial Title: A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy, or therapies known to provide clinical benefit, or for whom efficacious standard therapy or any other therapy known to provide clinical benefit does not exist~* Participant has no history of prior cancer, except certain cervical, skin, or prostate cancers, or has undergone potentially curative therapy with no evidence of disease for 5 years~* At least 18 years of age~* Participant is able to swallow oral medications~* For participants enrolled in the MTD expansion cohorts, must have a diagnosis of Kirsten rat sarcoma viral oncogene homolog (KRAS) tumor-type non small-cell lung cancer (NSCLC). Additional tumor types (with specific mutations) may be added to the MTD expansion cohorts after discussion between Sponsor and Investigator~Exclusion Criteria:~* Participant has had chemotherapy, radiotherapy or biological therapy within 4 weeks of entering the study~* Participant is currently participating in or has participated in a study of an investigational compound or device within 30 days or 5x the compound's half-life of Cycle 1, Day 1~* Participant has known central nervous system metastases and/or carcinomatous meningitis~* Participant has a primary central nervous system tumor or spinal cord compression~* Participant is, at the time of signing informed consent, a regular user (including recreational use) of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse~* Participant is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study~* Participant is human immunodeficiency virus (HIV) positive~* Participant is has history of hepatitis B or C or active hepatitis A~* Participant has a history or current evidence of heart disease~* Participant has uncontrolled high blood pressure~* Participant has poorly controlled diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-2206 45 mg QOD + AZD6244 75 mg QD (Type: EXPERIMENTAL): Participants receive MK-2206 45 mg oral tablets once every other day (QOD) PLUS AZD6244 75 mg oral capsules once daily (QD) starting on Day 1 of each 28-day cycle.
- MK-2206 45 mg QOD + AZD6244 75 mg BID (Type: EXPERIMENTAL): Participants receive MK-2206 45 mg oral tablets QOD PLUS AZD6244 75 mg oral capsules twice daily (BID) starting on Day 1 of each 28-day cycle.
- MK-2206 90 mg QW + AZD6244 50 mg BID (Type: EXPERIMENTAL): Participants receive MK-2206 90 mg oral tablets once weekly (QW) PLUS AZD6244 50 mg oral capsules BID starting on Day 1 of each 28-day cycle.
- MK-2206 90 mg QW + AZD6244 75 mg QD (Type: EXPERIMENTAL): Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules QD starting on Day 1 of each 28-day cycle.
- MK-2206 90 mg QW + AZD6244 75 mg BID (Type: EXPERIMENTAL): Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules BID starting on Day 1 of each 28-day cycle.
- MK-2206 90 mg QW + AZD6244 100 mg QD (Type: EXPERIMENTAL): Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
- MK-2206 90 mg QW + AZD6244 150 mg QD (Type: EXPERIMENTAL): Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 150 mg oral capsules QD starting on Day 1 of each 28-day cycle.
- MK-2206 100 mg QW + AZD6244 100 mg QD (Type: EXPERIMENTAL): Participants receive MK-2206 100 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
- MK-2206 135 mg QW + AZD6244 100 mg QD (Type: EXPERIMENTAL): Participants receive MK-2206 135 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).